Hormonal, psychological, and alcohol craving changes after m- Chlorophenylpiperazine administration in alcoholics

Alcoholism: Clinical and Experimental Research

Volumn 21, Issue 2, 1997, Pages 220-227

  Buydens Branchey, L ^a,b   Branchey, M ^a   Fergeson, P ^a   Hudson, J ^a   McKernin, C ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

'High' Feeling; Alcoholics; Cortisol; m CPP Challenge; Prolactin

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; HYDROCORTISONE; PROLACTIN;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; HEADACHE; HORMONE RESPONSE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROENDOCRINE SYSTEM; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM;

EID: 0030989612     PISSN: 01456008     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1530-0277.1997.tb03753.x     Document Type: Article

References (38)

1. Ballenger JC, Goodwill FK, Major LE, Brown GL: Alcohol and central serotonin metabolism in man. Arch Gen Psychiatry 36:224-226, 1979
2. Oreland L, von Knorring L, von Knorring AL, Bohrnan M: Studies on the connection between alcoholism and low platelet monoamine oxiactivity, in Parvez S, Burns Burrow Y, Parvez H (eds): Progress in Alcohol Research. Utrecht, VNU Science Press, 1985, p 83
3. Buydens-Branchey L, Branchey M, Noumair D, Lieber CS: Age of alcoholism onset: Relationship to susceptibility to serotonin precursor availability, Arch Gen Psychiatry 48:231-236, 1989
4. Roy A, Virkkunen M, Guthrie S, Linnoila M: Indices of serotonin and glucose metabolism in violent offenders, arsonists and alcoholics, Ann NY Acad Sci 487:202-220, 1986
5. Benkelfat C, Murphy DL, Hill JI, George DT, Nutt D, Linnoila M: Ethanollike properties of the serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients. Arch Gen Psychiatry 48:383, 1991
6. Krystal JH, Webb E, Cooney N, Kranzler HR, Charney DS: Specificity of ethanollike effects effects by serotonergic and noradrenergic mechanisms. Arch Gen Psychiatry 51:898-911, 1994
7. Kahn RS, Knott P, Gabriel S, Dumont K, Mastroianni L, Davidson M: Effect of m-CPP on plasma homovanillic acid in healthy subjects, Biol Psychiatry 32:1055-1061, 1992
8. Buydens-Branehey L, Branehey M, Fergeson P, Hudson J, McKernin C: Craving for cocaine in cocaine addicts: role of serotonergic mechAm J Addict (in press)
9. Handelsman L: Serotonergic challenges in cocaine addicts alcoholics. Abstract at the Americans Psychiatric Association meeting, San Francisco, CA, 1993
10. Spitzer RL, Williams JB, Gibbon M, First MB: User's Guide for the Structured Clinical Interview of the DSM-III-R. Washington, D.C., American Psychiatric Press, 1990
11. Suckow RF, Cooper TB, Kahn RS: High-performance liquid Chromatographic method for the analysis of plasma m-chlorophenylpiperazine. J Chromatogr 528:228-234, 1990
12. Hoyder D: Functional correlates of serotonin 5-HT, recognition sites. J Recept Res 8:59-81, 1988
13. Hamik A, Peroutka SJ: l-(m-Chlorophenyl) piperazine interactions with neurotransmitter receptors in the human brain, Biol Psychiatry 25: 569-575, 1989
14. Glennon RA, Ismiaiel AE, McCarthy BG: Binding of arylpiperazines to 5-HT, serotonin receptors: Results of a structure-affinity study, Eur J Pharmacol 168:387-392, 1989
15. B receptor ligands exist? Arch Pharmacol 339:675-683, 1989
16. Shen Y, Monsnia FJ Jr, Metcalf MA: Molecular cloning and expression of a 5-hydroxytryptamine receptor subtype. J Biol Chem 268: 18200-18204, 1993
17. Lee MA, Meltzer HY: Neuroendocrine responses to serotonergic agents in alcoholics. Biol Psychiatry 30:1017-1030, 1991
18. Hollander E, DeCaria CM, Niteseu A, Gully R, Suckow RF, Cooper TB, German JM, Klein DF, Liebowitz MR: Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 49:21-28, 1992
19. Hadigan CM, Walsh BT, Buttinger C, Hollander E: Behavioral and neuroendocrine responses to meta-CPP in anorexia neurosa. Biol Psychiatry 37:504-511, 1995
20. Buydens-Branchey L, Branehey M, Fergeson P, Hudson J, MeKernin C: The m-CPP challenge test in cocaine addicts: Hormonal and psychological responses, Biol Psychiatry (in press)
21. Kahn RS, Kalus O, Wetzler S, Cahn W, Asnis GM, van Praag HM: Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects. Psychiatry Res 33:189-198, 1990
22. Mueller EA, Murphy DL, Sunderland T: Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: Evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacology 89:388-391, 1986
23. Seibyl JP, Krystal JH, Price LH: Effects of ritanserin on the behavioural, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazinc in healthy human subjects. Psychiatry Res 38:227-236, 1991
24. Hollander E, Cohen IJ, DeCaria C, Saoud JB, Stein DJ, Cooper TB, Islam NN, Liebowitz ME, Klein DF: Timing of neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels In OCD. Biol Psychiatry 34:407-413, 1993
25. Fuller RW: Serotonergic stimulation of pituitary-adrenocortical function in rats. Neuroendocrinology 32:118-127, 1981
26. Fuller RW, Snoddy HD: Effect of serotonin-releasing drugs on serorn corticosterone concentration in rats. Neuroendocrinology 31:96100, 1980
27. Gibbs DM, Vale W: Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophyseal portal blood. Res 280:176-179, 1983
28. Amit Z, Brown Z, Sutherland A, Rockman G, Gill K, Selvaggi N: Reduction in alcohol intake in humans as a function of treatment with zimelidine: Implications for treatment, in: Naranjo CA, Sellers EM (eds): Research Advances in New Psychopharmacological Treatments for Alcoholism. Amsterdam, Elsevier Science Publishers B.V., 1994, p 189
29. Naranjo CA, Sullivan JT, Kadlec KE, Woodley-Remus, DV, Kennedy G, Sellers EM: Differential effects of viqualine on alcohol intake and other consummatory behaviors. Clin Pharmacol Ther 46:301-309, 1989
30. Naranjo CA, Poulos CX, Kadlec KE, Lanctot KL: Citalopram decreases desirability, liking and consumption of alcohol in alcohol-dependent drinkers. Clin Pharmacol Ther 51:729-739, 1992
31. Gorelick DA, Paredes A: Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res 16:261-265, 1992
32. Engel JA, Enerback C, Fahhlke C, Hulthe P, Hard E, Johannessen K, Svensson L, Söderpalm B: Serotonergic and dopaminergic involvement in ethanol intake, in Naranjo CA, Sellers EM (eds): Novel Pharmacological Interventions for Alcoholism. New York, Springer-Verlag, 1992, p 68
33. Naranjo CA, Bremmer KE: Serotonin-altering medications and desire, consumption and effects of alcohol-treatment implications, in Jansson B, Jörnvall H, Rydberg U, Tenenius L, Valle BL (eds): Toward a Molecular Basis of Alcohol Use and Abuse. Basel, Birkhauser Verlag, 1994, p 209
34. Hollander E, Stein DJ, DeCaria CM, Cohen L, JB, Skodol AE, Kellman DK, Rosnick L, Oldham JM: Serotonin sensitivity in borderline personality disorder: preliminary findings. Am J Psychiatry 151:2: 277-280, 1994
35. Freedman DX: Hallucinogenic drug research - If so, so what? Symposium, summary and commentary. Pharmacol Biochem Behav 24:407-415, 1986
36. Jacobs BL: How hallucinogenic drugs work. Am Scientist 75:386-392, 1987
37. Callahan PM, Cunningham KA: Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-CPP. Eur J Pharmacol 257:27-38, 1994
38. Sanders-Bush E, Breeding M: Choroid plexus epithelial cells in primary culture: A model of 5-HT1C receptor activation by hallucinogenic drugs. Psychopharmacology (Berl) 105:340, 1991